NCT01497600View on ClinicalTrials.gov

Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

August 31, 2004

Study Completion Date

August 31, 2004

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

insulin detemir

Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)

DRUG

insulin NPH

Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)

Trial Locations (1)

91911

Novo Nordisk Investigational Site, Chula Vista

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY